- Home
- VCIG vs HCWB Comparison
VCIG vs HCWB Comparison
Compare VCIG & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCIG
- HCWB
- Stock Information
- Founded
- VCIG 2013
- HCWB 2018
- Country
- VCIG Malaysia
- HCWB United States
- Employees
- VCIG N/A
- HCWB N/A
- Industry
- VCIG Diversified Commercial Services
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- VCIG Consumer Discretionary
- HCWB Health Care
- Exchange
- VCIG Nasdaq
- HCWB Nasdaq
- Market Cap
- VCIG 7.5M
- HCWB 8.4M
- IPO Year
- VCIG 2023
- HCWB 2021
- Fundamental
- Price
- VCIG $1.20
- HCWB $2.11
- Analyst Decision
- VCIG
- HCWB Strong Buy
- Analyst Count
- VCIG 0
- HCWB 1
- Target Price
- VCIG N/A
- HCWB $35.00
- AVG Volume (30 Days)
- VCIG 9.3M
- HCWB 125.7K
- Earning Date
- VCIG 10-06-2025
- HCWB 11-14-2025
- Dividend Yield
- VCIG N/A
- HCWB N/A
- EPS Growth
- VCIG N/A
- HCWB N/A
- EPS
- VCIG 0.98
- HCWB N/A
- Revenue
- VCIG $32,903,041.00
- HCWB $422,026.00
- Revenue This Year
- VCIG N/A
- HCWB $178.64
- Revenue Next Year
- VCIG N/A
- HCWB N/A
- P/E Ratio
- VCIG $1.20
- HCWB N/A
- Revenue Growth
- VCIG 24.77
- HCWB N/A
- 52 Week Low
- VCIG $0.91
- HCWB $1.98
- 52 Week High
- VCIG $4,644.01
- HCWB $100.80
- Technical
- Relative Strength Index (RSI)
- VCIG 37.80
- HCWB 26.91
- Support Level
- VCIG $1.00
- HCWB $2.30
- Resistance Level
- VCIG $2.18
- HCWB $3.78
- Average True Range (ATR)
- VCIG 0.29
- HCWB 0.44
- MACD
- VCIG 0.09
- HCWB -0.09
- Stochastic Oscillator
- VCIG 23.28
- HCWB 2.87
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.